Atypical antipsychotics such as olanzapine and clozapine are effective at treating the multiple domains of schizophrenia, with a low risk of extra-pyramidal side-effects. However a major downfall to their use is metabolic side-effects particularly weight gain/obesity, which occurs by unknown mechanisms. The present paper explores the potential candidature of histaminergic neurotransmission in the mechanisms of atypical antipsychoticinduced weight gain, with a focus on the histaminergic H1 and H3 receptors. Olanzapine and clozapine have a high affinity for the H1 receptor, and meta-analyses show a strong correlation between risk of weight gain and H1 receptor affinity. In addition, olanzapine treatment decreases H1 receptor binding and mRNA expression in the rat hypothalamus. Furthermore, a complex role is emerging for the histamine H3 receptor in the control of hunger. The H3 receptor is a pre-synaptic autoreceptor that inhibits the synthesis and release of histamine, and a heteroreceptor that inhibits other neurotransmitters such as serotonin (5-HT), noradrenaline (NA) and acetylcholine (ACh), which are also implicated in the regulation of food intake. Thus, the H3 receptor is in a prime position to regulate food intake, both through its control of histamine and its influence on other feeding pathways. We proposed that a mechanism for atypical antipsychotic-induced weight gain may be partly through the H3 receptor, as a drug-induced decrease in H1 receptor activity may decrease histamine tone through the H3 autoreceptors, compounding the weight gain problem. In addition, atypical antipsychotics may affect food intake by influencing 5-HT, NA and ACh release via interactions with the H3 heteroreceptor.
Introduction
Antipsychotic drugs play a key role in the treatment of schizophrenia and are increasingly prescribed for other health issues such as bipolar disorder, major depression, dementia and substance abuse (Centorrino et al., 2002) . In addition, these drugs are utilized in hospital emergency departments to assist patients presenting with acute psychosis (Ballerini et al., 2003) .
Atypical antipsychotic drugs (such as olanzapine and clozapine) are considered to possess superior efficacy in treating the positive, negative and cognitive domains of schizophrenia compared to conventional 'typical' antipsychotics, particularly in schizophrenia patients that are non-responsive to conventional drug therapy (Matza et al., 2005; Keefe et al., 2006) . Differing to the typical profile, atypical antipsychotic drugs generally affect a range of receptors, including adrenergic, histaminergic, serotonergic and muscarinic, with less antagonistic effects on D2 receptors than typical antipsychotic drugs and therefore a lower propensity to cause extra-pyramidal side-effects (Richelson and Souder, 2000; Roth et al., 2004) . However, a significant side-effect of atypical antipsychotic drug-use is weight gain/obesity, which is of social and clinical importance as it may lead to further complications such as noncompliance of medication, diabetes and cardiovascular disease. Despite this significance, the mechanisms behind atypical antipsychoticinduced weight gain remain unclear, perhaps because these drugs differ markedly in their pharmacological profiles, and because of the complex and well-preserved interactions between the systems involved in energy balance regulation. Understanding the mechanisms causing this side-effect will help to improve future pharmacotherapies for schizophrenia, as patients commonly undergo many years of drug treatment due to the chronicity of the disease. The present paper explores the potential candidature of histaminergic neurotransmission in the mechanisms of atypical antipsychotic-induced weight gain, with a focus on the histaminergic H1 and H3 receptors. We propose that the H3 receptor may impact histaminergic H1 signaling, as well as other neurotransmitter systems such as the serotonergic, noradrenaline and acetylcholine pathways, to influence body energy balance regulation.
